A systematic review and meta-analysis of 20 studies published in 2018 in Lancet Oncology included 11,351 people with various types of metastatic cancer. Researchers reported men receiving checkpoint inhibitors had a 28% reduced risk of dying during the study period vs a 14% reduced risk for women.
However, a July 2020 report in Biomedicines found that there was an overall survival benefit of immunotherapy for both men and women. No statistically significant difference between men and women's responses to immunotherapy were found.